Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $28

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $26 to $28.
byBenzinga Newsdesk
March 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $26 to $28.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Where Zscaler Stands With Analysts

By Benzinga Insights
October 6, 3:30 PM
Over the past 3 months, 21 analysts have published their opinion on Zscaler (NASDAQ:ZS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ZS